Mehabe score: 3 G Factor: 5 Piotski Score: 9 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 5 and Piotski score of 9.
Description
Lotus Eye Hospital & Institute is mainly in the field of ophthalmology (Eye) and its related operation.(Source : 201903 Annual Report Page No:58)Site:LOTUSEYE
Market Cap:
Rs 110 cr
Price:
52.8
Trading pe:
x
Book-value:
24.4/share
Div yield:
0.00 %
Earning yield:
-0.27%
Face-value:
10.0/share
52week high:
59.00
52week low:
26.00
Technical Analysis
Stock trades at 52.8, above its 50dma 46.37. It also trades above its 200dma 38.97. The stock remains bullish on techicals
The 52 week high is at 59.00 and the 52week low is at 26.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– has reduced debt.
– is almost debt free.
Weakness
– Though the company is reporting repeated profits, it is not paying out dividend
– has low interest coverage ratio.
-The company has delivered a poor sales growth of 6.28% over past five years.
– has a low return on equity of 2.56% for last 3 years.
Competition
– The industry trades at a mean P/E of 38.9x. Max Healthcare trades at the industry’s max P/E of 488.73x. LOTUSEYE trades at a P/E of x
– Industry’s mean G-Factor is 5.0 while the mean Piotski score is 9.0. LOTUSEYE has a G-Factor of 5 and Piotski scoreof 9.
– Average 1 month return for industry is 9.6%. The max 1- month return was given by Lotus Eye Hospit: a return of 21.91 %
Quarterly Results
Sales for period ended Mar 2021 is Rs 10.57 cr compared to Rs 8.17 cr for period ended Mar 2020, a rise of 29.4%
Company reported operating profit of Rs 1.76 cr for period ended Mar 2021, operating profit margin at 16.7 %.
Operating profit was negative for the same period last year thus company has improved its margins this year
The EPS for Mar 2021 was Rs 0.53 compared to Rs 0.5 for previous quarter ended Dec 2020 and Rs -0.46 for Mar 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 32.37 cr for period ended Mar 2021 vis-vis sales of Rs 40.55 cr for the period ended Mar 2020, a fall of 25.3%. The 3 year sales cagr stood at -5.2%.
Operating margins expanded to 11.0% for period ended Mar 2021 vis-vis 9.74% for period ended Mar 2020, expansion of 126.0 bps.
Net Profit reported at Rs 1.57 cr for period ended Mar 2021 vis-vis sales of Rs 1.06 cr for the period ended Mar 2020, rising 32.5%.
Company reported a poor Net Profit CAGR of -3.6% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has had stable/constant Return on Equity (RoE) metric. The RoE on Last Year basis was 3.0% compared to 3.0% over the last 3 Years. – The stock has given a return of 70% on a 1 Year basis vis-vis a return of 30% over the last 3 Years. – The compounded sales growth on a TTM bassis is -29% vis-vis a compounded sales growth of 6% over the last 3 Years. – The compounded profit growth on a TTM basis is -108% vis-vis a compounded profit growth of 47% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has remained largely constant. The Mar 2021 public holding stood at 42.26% vis-vis 42.29% for Dec 2020
Conclusion
– has reduced debt.
– is almost debt free. – Though the company is reporting repeated profits, it is not paying out dividend
– has low interest coverage ratio.
-The company has delivered a poor sales growth of 6.28% over past five years.
– has a low return on equity of 2.56% for last 3 years.
